Real-World Data Confirm Alectinib's Edge Over Crizotinib in ALK+ NSCLC

A new real-world analysis in Lung Cancer examines whether clinical trial results for ALK-positive non-small cell lung cancer (NSCLC) treatments hold up in broader patient populations. Led by Jorge J. Nieva, MD, of the Keck School of Medicine at USC, the study addresses a common limitation of clinical trials: they're conducted under controlled conditions with strict eligibility criteria, often excluding older, sicker, or more complex patients who make up much of the real-world patient population.

Using insurance claims data from 940 patients treated between 2016 and 2024, researchers compared outcomes across five ALK tyrosine kinase inhibitors (TKIs): crizotinib (Xalkori), alectinib (Alecensa), brigatinib (Alunbrig), lorlatinib (Lorbrena), and ceritinib (Zykadia). The clearest finding was that alectinib significantly outperformed crizotinib, with a median overall survival of 46.5 months vs crizotinib and a median time on treatment of 33.5 months. Sample sizes for brigatinib and lorlatinib were too small to draw firm conclusions.

Notably, these real-world results closely mirrored those of the landmark ALEX trial, which had originally established alectinib's superiority over crizotinib in a controlled setting. Nieva emphasized that this consistency is reassuring, especially as generic versions of older first-generation drugs become available—the data suggest that switching to cheaper generics wouldn't serve patients as well as continuing to use newer, more effective agents.

The study also highlights why real-world data matters: many patients never make it into clinical trials due to poor performance status, secondary cancers, organ dysfunction, or simply lack of access to trial-offering academic medical centers. This means trial populations tend to skew healthier and wealthier than typical patients.

Looking ahead, Nieva pointed to open questions about newer third- and fourth-generation ALK inhibitors like lorlatinib, which shows strong efficacy but also notable neurocognitive toxicity. He hopes future research can clarify how dose adjustments for these more toxic agents affect survival in everyday clinical practice, beyond the tightly controlled trial setting.

Read the full interview with Dr Nieva.